Market Overview

Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill

Share:
Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company that mostly focuses on developing therapies for the treatment of complement-mediated diseases and disorders of the central nervous system, saw its stock soar nearly 40 percent Thursday morning.

What Happened

American congressional officials released Wednesday a more than 2,000-page spending package, which includes a "complicated policy that represents a major win" for Omeros, STAT News' Erin Mershon reported. Specifically, Omeros can benefit from two additional years of extra Medicare reimbursement for its cataract surgery drug Omidria.

Why It's Important

The specific wording of the spending bill likely implies the new policy will only favorably impact Omeros and its product and "almost no other drug companies," Mershon said. Stat News' Adam Feuerstein Tweeted that Omeros benefited from "special-interest lobbying."

What's Next

Despite the huge percent surge Thursday morning above the $15 mark, the stock is still trading notably below its 52-week high of $27.09. Bullish investors are hoping the momentum can be sustained throughout the pre-market trading session and continue rising over time.

At time of publication, the stock was up 35.4 percent at $15.76.

Related Links:

Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use

Can Omeros Top-Line Growth Continue?

Posted-In: Biotech Government News Politics Top Stories Movers Media Trading Ideas Best of Benzinga

 

Related Articles (OMER)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

21 Stocks Moving In Thursday's Pre-Market Session

A Peek Into The Markets: U.S. Stock Futures Tumble Ahead Of Economic Data